

Disclosures and Disclaimer

This book is not intended as investment advice of any kind. The author, through funds in his limited liability company, Heng Ren Partners LLC (“Heng Ren”), has had an investment in Sinovac since 2013. The book may contain opinion, analysis and commentary based on reported facts, and you should assume that as of the publication date of this book, Heng Ren (including its members, partners, affiliates, employees, and/or consultants) along with its clients and/or investors has a position in all stocks covered herein, and therefore has a financial interest in the companies discussed herein. Following publication of this book, Heng Ren intends to continue transacting in the securities covered herein, and may be long, short, or neutral at any time hereafter regardless of the reporting or analysis contained herein.

Additionally, the author, through Heng Ren, is involved in a shareholder rights lawsuit against Sinovac in the U.S. District Court for the District of Massachusetts, styled as *Heng Ren Investments LP v. Sinovac Biotech Ltd.*, et al. 1:19-cv-11612-NMG. The lawsuit is pending as of the date of publication.